1.

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.

2.

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.

3.

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.

1.

GAIN IN LIFE EXPECTANCY IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION TREATED EARLY WITH ENALAPRIL: A 23-YEAR FOLLOW-UP OF SOLVD COHORT IN BELGIUM

1.

Established and novel gender dimorphisms in type 2 diabetes mellitus: Insights from a multiethnic cohort.

2.

Established and novel gender dimorphisms in type 2 diabetes mellitus: Insights from a multiethnic cohort.

3.

Established and novel gender dimorphisms in type 2 diabetes mellitus: Insights from a multiethnic cohort.

1.

LONG-TERM EFFECT OF EARLY ENALAPRIL THERAPY ON CAUSES OF DEATH IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION: A 27-YEAR FOLLOW-UP OF SOLVD IN BELGIUM

1.

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

2.

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

3.

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence.

1.

Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.

2.

Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.

3.

Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.